Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALDR is in the long-term down -80% below S&P in 5 years.
Description: Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-4.47||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-3.91|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-0.14%||ROE||-0.15%||ROI|
|Current Ratio||36.49||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.03|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||190.83 M||Cash From Investing Activities||-11.65 M||Cash From Operating Activities||-16.05 M||Gross Profit|
|Net Profit||-14.65 M||Operating Profit||-14.71 M||Total Assets||242.94 M||Total Current Assets||241.6 M|
|Total Current Liabilities||6.62 M||Total Debt||Total Liabilities||6.78 M||Total Revenue|
|High 52 week||18.6||Low 52 week||9.8||Last close||11.65||Last change||1.48%|
|RSI||60.85||Average true range||0.75||Beta||1.6||Volume||534.94 K|
|Simple moving average 20 days||9.03%||Simple moving average 50 days||-3.31%||Simple moving average 200 days||-14.66%|
|Performance Week||13.11%||Performance Month||4.86%||Performance Quart||-13.45%||Performance Half||-3.72%|
|Performance Year||4.48%||Performance Year-to-date||13.66%||Volatility daily||4.21%||Volatility weekly||9.41%|
|Volatility monthly||19.28%||Volatility yearly||66.78%||Relative Volume||264.97%||Average Volume||887.27 K|
|New High||New Low|
2019-06-11 08:02:54 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-06-10 08:05:19 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-06-04 14:18:53 | Imagine Owning Alder BioPharmaceuticals NASDAQ:ALDR While The Price Tanked 65%
2019-06-04 08:05:11 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-05-24 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-05-14 16:05:00 | Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences
2019-05-07 11:21:35 | Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc ALDR
2019-05-07 08:04:43 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-05-06 09:58:01 | Geron's GERN Q1 Earnings Beat, Revenues Miss, Stock Up
2019-05-03 13:00:00 | Bob Azelby awaits approval of Alder’s migraine drug
2019-05-03 07:27:15 | Edited Transcript of ALDR earnings conference call or presentation 2-May-19 9:00pm GMT
2019-05-02 23:58:44 | Alder BioPharmaceuticals, Inc. ALDR Q1 2019 Earnings Call Transcript
2019-05-02 18:27:24 | Alder BioPharmaceuticals: 1Q Earnings Snapshot
2019-04-30 08:04:50 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-04-26 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure
2019-04-23 16:38:39 | Why This Migraine-Focused Biotech Stock Could Be The Next Takeover
2019-04-23 08:00:00 | Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting
2019-04-22 16:34:57 | U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
2019-04-19 16:19:56 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-04-12 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-04-08 16:05:00 | Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer
2019-04-05 19:10:05 | Alder Biopharmaceuticals CEO: Spreading migraine awareness
2019-04-02 08:00:00 | Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference
2019-03-12 10:28:30 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-03-06 08:02:57 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-03-05 08:03:14 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
2019-03-01 08:30:00 | Recent Analysis Shows McDermott International, Nu Skin Enterprises, Marcus, Keysight Technologies, Alder BioPharmaceuticals, and LendingTree Market Influences — Renewed Outlook, Key Drivers of Growth
2019-02-27 20:07:36 | Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
2019-02-26 20:40:39 | Edited Transcript of ALDR earnings conference call or presentation 25-Feb-19 10:00pm GMT
2019-02-25 22:06:01 | Alder BioPharmaceuticals Inc ALDR Q4 2018 Earnings Conference Call Transcript
2019-02-25 15:00:00 | Alder Biopharmaceuticals, Inc. to Host Earnings Call
2019-02-22 16:16:52 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-02-14 15:30:43 | Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
2019-02-14 07:20:00 | Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America — Fundamental Analysis, Key Performance Indications
2019-02-12 08:52:01 | Molina Healthcare MOH Q4 Earnings & Revenues Top Estimates
2019-02-08 10:05:03 | Ensign Group's ENSG Q4 Earnings Top Estimates, Surge Y/Y
2019-02-08 10:03:03 | MEDNAX MD Q4 Earnings Surpass Estimates, Increase Y/Y
2019-02-07 10:34:03 | Is a Beat in Store for Molina Healthcare MOH Q4 Earnings?